Vanguard Group Inc Cognition Therapeutics Inc Transaction History

Vanguard Group Inc

$5.12 Trillion
Q2 2024

A detailed history of Vanguard Group Inc transactions in Cognition Therapeutics Inc stock. As of the latest transaction made, Vanguard Group Inc holds 1,147,554 shares of CGTX stock, worth $585,252. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,147,554

Previous 921,680 24.51%

Holding current value

$585,252

Previous $1.68 Million 13.54%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.66 - $2.62 $374,950 - $591,789	225,874 Added 24.51%	1,147,554 $1.9 Million
Q1 2024 May 10, 2024	BUY	$1.78 - $2.53 $356,224 - $506,318	200,126 Added 27.74%	921,680 $1.68 Million
Q4 2023 Feb 14, 2024	BUY	$0.96 - $2.42 $33,271 - $83,872	34,658 Added 5.05%	721,554 $1.33 Million
Q3 2023 Nov 14, 2023	BUY	$1.25 - $1.9 $23,088 - $35,094	18,471 Added 2.76%	686,896 $989,000
Q2 2023 Aug 14, 2023	BUY	$1.56 - $3.38 $39,054 - $84,618	25,035 Added 3.89%	668,425 $1.22 Million
Q1 2023 May 15, 2023	BUY	$1.51 - $2.3 $148,736 - $226,552	98,501 Added 18.08%	643,390 $1.27 Million
Q4 2022 Feb 10, 2023	BUY	$1.17 - $3.51 $168,112 - $504,337	143,686 Added 35.81%	544,889 $1.14 Million
Q3 2022 Nov 14, 2022	BUY	$1.63 - $3.6 $538,361 - $1.19 Million	330,283 Added 465.71%	401,203 $762,000
Q2 2022 Aug 12, 2022	BUY	$1.5 - $3.45 $18,486 - $42,517	12,324 Added 21.03%	70,920 $150,000
Q1 2022 May 13, 2022	BUY	$2.41 - $6.9 $40 - $117	17 Added 0.03%	58,596 $161,000
Q4 2021 Feb 14, 2022	BUY	$5.1 - $12.98 $298,752 - $760,355	58,579 New	58,579 $371,000

Others Institutions Holding CGTX

# of Institutions

Shares Held

7.64M

Call Options Held

Put Options Held

View Full List

About COGNITION THERAPEUTICS INC

Ticker CGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,710,700
Market Cap $11.6M
Description
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical tr...

More about CGTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Cognition Therapeutics Inc Transaction History